FDA To Review Pfizer’s Abrilada For Humira Interchangeability
Adalimumab Biosimilar Is Set For US Launch In July 2023
Executive Summary
The US FDA is reviewing Pfizer’s Humira biosimilar, Abrilada, to assess whether the compound can be granted an interchangeability designation with the original drug.
You may also be interested in...
Interchangeable Exclusivity: Pfizer To Rival Boehringer On Humira Biosimilar After US FDA Decision
FDA decision ends Boehringer Ingelheim’s exclusivity for interchangeable biosimilar of Humira after just a few months. Pfizer reveals pricing and launch information for its Abrilada version of adalimumab.
FDA Decision On Interchangeable Exclusivity Allows Pfizer To Rival Boehringer On Adalimumab
An FDA decision around the timing of first interchangeable biosimilar exclusivity has brought to an end Boehringer Ingelheim’s time on the market with a unique interchangeable Humira rival, with the agency also granting interchangeability for Pfizer’s Abrilada version of adalimumab.
Generics Bulletin Explains: The Next Wave Of US Humira Biosimilars
Following Amgen’s debut of the first US Humira rival earlier this year, as many as eight further FDA-approved adalimumab biosimilars are about to launch. Generics Bulletin breaks down all the different players and how they are positioning themselves in such a competitive market.